NephroGenex Protocol PRY-311 : A Phase 3 Randomized, Double-Blind,Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes.

Administered By

Awarded By

Contributors

Start/End

  • July 1, 2014 - February 13, 2018